Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
COVID-19
About this trial
This is an interventional prevention trial for COVID-19
Eligibility Criteria
Inclusion Criteria:
- 18 years or older, relatively good health, negative for pre-existing SARS-CoV-2 antibodies, negative for SARS-CoV-2 infection
Exclusion Criteria:
- Active COVID-19 infection by PCR testing, pre-existing SARS-CoV-2 antibodies, pregnant, known hypersensitivity to GM-CSF, known immune deficiency disease, on active treatment with immunosuppressive agent or corticosteroid, participated in previous COVID-19 trial
Sites / Locations
- Rumah Sakit Umum Pusat Dr. Kariadi
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
0.1 mg antigen, 0 mcg GM-CSF
0.33 mg antigen, 0 mcg GM-CSF
1.0 mg antigen, 0 mcg GM-CSF
0.1 mg antigen, 250 mcg GM-CSF
0.33 mg antigen, 250 mcg GM-CSF
1.0 mg antigen, 250 mcg GM-CSF
0.1 mg antigen, 500 mcg GM-CSF
0.33 mg antigen, 500 mcg GM-CSF
1.0 mg antigen, 500 mcg GM-CSF
Dendritic cells previously incubated with 0.1 mcg antigen
Dendritic cells previously incubated with 0.33 mcg antigen
Dendritic cells previously incubated with 1.0 mcg antigen
Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 250 mcg GM-CSF
Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 250 mcg GM-CSF
Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 250 mcg GM-CSF
Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 500 mcg GM-CSF
Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 500 mcg GM-CSF
Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 500 mcg GM-CSF